Author

J. Gossen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:deep learning· 1 Organism:human· 1 Approach:mechanistic / dynamical model· 1 Organism:mouse· 1 Assay:proteomics· 1 Approach:statistical model· 1 Assay:structural biology· 1

Frequent Co-Authors

G. Rossetti· 2 shared A. Hanke· 1 shared A. R. Beccari· 1 shared A. Zaliani· 1 shared B. P. Joseph· 1 shared B. Tirosh· 1 shared C. Bergh· 1 shared C. Manelfi· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

G. Rossetti

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

KIRA6 is an effective and versatile mast cell inhibitor of IgE-mediated activation

T. Wilhelm, V. Wunderle, S. Boukeileh, J. Gossen, M. A. Margreiter, R. Sakurov, S. Capellmann, M. Schwoerer, N. Ahmed, G. Bronneberg, M. Arock, C. Martin, T. Schubert, F. Levi-Schaffer, G. Rossetti, , M. Huber

This study identifies KIRA6 as a dual inhibitor of LYN and FYN that suppresses IgE-mediated mast cell activation and inflammation.

bioRxiv · Apr 18, 2024Immunology

A blueprint for high affinity SARS-CoV-2 Mpro inhibitors from activity-based compound library screening guided by analysis of protein dynamics

J. Gossen, S. Albani, A. Hanke, B. P. Joseph, C. Bergh, M. Kuzikov, E. Costanza, C. Manelfi, P. Storici, P. Gribbon, A. R. Beccari, C. Talarico, F. Spyrakis, E. Lindahl, A. Zaliani, , G. Rossetti

The paper identifies a blueprint for high affinity SARS-CoV-2 Mpro inhibitors by analyzing protein dynamics and redefining druggability through virtual screening and pharmacophore modeling.

bioRxiv · Dec 14, 2020Biophysics